Angiogenesis in neurological disorders: a review

References

• de Almodovar CR ZSCP. Angiogenesis in the central nervous system. In: Angiogenesis: an integrative approach from science to medicine. New York: Springer; 2008.
   Google Scholar
• Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, et al.. SSeCKS regulates angiogenesis and tight junction formation in blood–brain barrier. Nat Med. 2003;9:900–6.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001;61:6020–4.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al.. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607–12.
   PubMed Web of Science ®Google Scholar
• Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, et al.. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999;59:4129–35.
   PubMed Web of Science ®Google Scholar
• Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 1994;54:4564–8.
   PubMed Web of Science ®Google Scholar
• Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, et al.. Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol. 2005;12:1232–40.
   PubMed Web of Science ®Google Scholar
• Plate KH, Mennel HD. Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol. 1995;47:89–94.
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavstev I, et al.. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–63.
   PubMed Web of Science ®Google Scholar
• Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, et al.. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol. 1999;159:391–400.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. FEBS J. 2009;276:4636–43.
   PubMed Web of Science ®Google Scholar
• Demir R, Kayisli UA, Cayli S, Huppertz B. Sequential steps during vasculogenesis and angiogenesis in the very early human placenta. Placenta. 2006;27:535–9.
   PubMed Web of Science ®Google Scholar
• Seval Y, Korgun ET, Demir R. Hofbauer cells in early human placenta: possible implications in vasculogenesis and angiogenesis. Placenta. 2007;28:841–5.
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al.. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60.
   PubMed Web of Science ®Google Scholar
• Kleihues PBP, Plate KH, Ohgaki H, Cavenee WK. Tumors of the nervous system. Lyon: IARC Press; 2000.
   Google Scholar
• Birlik B, Canda S, Ozer E. Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas. Neuropathol Appl Neurobiol. 2006;32:532–8.
   PubMed Web of Science ®Google Scholar
• Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77:362–72.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987–9.
   PubMed Web of Science ®Google Scholar
• Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 1996;56:393–401.
   PubMed Web of Science ®Google Scholar
• Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al.. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63:2742–6.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–80.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611.
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys. 2004;58:927–31.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, et al.. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008;68:8733–42.
   PubMed Web of Science ®Google Scholar
• Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, et al.. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008;68:7342–51.
   PubMed Web of Science ®Google Scholar
• Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67:5064–6.
   PubMed Web of Science ®Google Scholar
• Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, et al.. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest. 2000;80:837–49.
   PubMed Web of Science ®Google Scholar
• Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998;153:1459–66.
   PubMed Web of Science ®Google Scholar
• Zadeh G, Qian B, Okhowat A, Sabha N, Kontos CD, Guha A. Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol. 2004;164:467–76.
   PubMed Web of Science ®Google Scholar
• Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010;3:775–81.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588–610.
   PubMed Web of Science ®Google Scholar
• Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005;7(4):436–51.
   PubMed Web of Science ®Google Scholar
• Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res. 2003;9(12):4578–85.
   PubMed Web of Science ®Google Scholar
• Kaye A, Laws E, editors. Brain tumors, an encyclopedic approach. 2nd ed. London: Churcill Livingstone; 2001.
   Google Scholar
• Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, et al.. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest. 1993;91:153–9.
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. Cancer. 2000;89:1102–10.
   PubMed Web of Science ®Google Scholar
• Shono T, Inamura T, Torisu M, Suzuki SO, Fukui M. Vascular endothelial growth factor and malignant transformation of a meningioma: case report. Neurol Res. 2000;22:189–93.
   PubMed Web of Science ®Google Scholar
• Lopes MB. Angiogenesis in brain tumors. Microsc Res Tech. 2003;60:225–30.
   PubMed Web of Science ®Google Scholar
• Kleihues PCW. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000.
   Google Scholar
• Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel–Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 1995;55:1358–64.
   PubMed Web of Science ®Google Scholar
• Gault J, Sarin H, Awadallah NA, Shenkar R, Awad IA. Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance. Neurosurgery. 2004;55:1–16; discussion 16–7.
   PubMed Web of Science ®Google Scholar
• Harrigan MR. Angiogenic factors in the central nervous system. Neurosurgery. 2003;53:639–60; discussion 60–1.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Lam T, Boudreau NJ, Bollen AW, Lawton MT, Young WL. Abnormal balance in the angiopoietin-tie2 system in human brain arteriovenous malformations. Circ Res. 2001;89:111–3.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Mesa-Tejada R, Quick CM, Bollen AW, Joshi S, Pile-Spellman J, et al.. Evidence of increased endothelial cell turnover in brain arteriovenous malformations. Neurosurgery. 2001;49:124–31; discussion 31–2.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Lawton MT, Wen G, Yang GY, Chaly T, Stewart CL, et al.. Gene microarray analysis of human brain arteriovenous malformations. Neurosurgery. 2004;54:410–23; discussion 23–5.
   PubMed Web of Science ®Google Scholar
• Rothbart D, Awad IA, Lee J, Kim J, Harbaugh R, Criscuolo GR. Expression of angiogenic factors and structural proteins in central nervous system vascular malformations. Neurosurgery. 1996;38:915–24; discussion 24–5.
   PubMed Web of Science ®Google Scholar
• Uranishi R, Baev NI, Kim JH, Awad IA. Vascular smooth muscle cell differentiation in human cerebral vascular malformations. Neurosurgery. 2001;49:671–9; discussion 679–80.
   PubMed Web of Science ®Google Scholar
• Uranishi R, Baev NI, Ng PY, Kim JH, Awad IA. Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations. Neurosurgery. 2001;48:359–67; discussion 367–8.
   PubMed Web of Science ®Google Scholar
• Zadeh G, Guha A. Angiogenesis in nervous system disorders. Neurosurgery. 2003;53:1362–74; discussion 74–6.
   PubMed Web of Science ®Google Scholar
• Seker A, Yildirim O, Kurtkaya O, Sav A, Gunel M, Pamir MN, et al.. Expression of integrins in cerebral arteriovenous and cavernous malformations. Neurosurgery. 2006;58:159–68; discussion 159–68.
   PubMed Web of Science ®Google Scholar
• Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, et al.. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994;8:1897–909.
   PubMed Web of Science ®Google Scholar
• Patan S. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res. 1998;56:1–21.
   PubMed Web of Science ®Google Scholar
• Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, et al.. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70–4.
   PubMed Web of Science ®Google Scholar
• Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, Haukaas SA. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009;182:2144–9.
   PubMed Web of Science ®Google Scholar
• Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, et al.. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89:385–9.
   PubMed Web of Science ®Google Scholar
• Stapleton CJ, Armstrong DL, Zidovetzki R, Liu CY, Giannotta SL, Hofman FM. Thrombospondin-1 modulates the angiogenic phenotype of human cerebral arteriovenous malformation endothelial cells. Neurosurgery. 2011;68:1342–53; discussion 1353.
   PubMed Web of Science ®Google Scholar
• Massague J. Receptors for the TGF-beta family. Cell. 1992;69:1067–70.
   PubMed Web of Science ®Google Scholar
• Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al.. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA. 2000;97:2626–31.
   PubMed Web of Science ®Google Scholar
• Langley RR, Fidler IJ. Tumor cell–organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007;28:297–321.
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3:53–7.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–8.
   PubMed Web of Science ®Google Scholar
• Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al.. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000;60:4959–67.
   PubMed Web of Science ®Google Scholar
• Stewart PA, Hayakawa K, Farrell CL, del Maestro RF. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood–brain barrier defect. J Neurosurg. 1987;67:697–705.
   PubMed Web of Science ®Google Scholar
• Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA, et al.. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell. 1991;65:25–35.
   PubMed Web of Science ®Google Scholar
• Harabin-Slowinska M, Slowinski J, Konecki J, Mrowka R. Expression of adhesion molecule CD44 in metastatic brain tumors. Folia Neuropathol. 1998;36:179–84.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.
   PubMed Web of Science ®Google Scholar
• Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–24.
   PubMed Web of Science ®Google Scholar
• Eichhorn ME, Kleespies A, Angele MK, Jauch KW, Bruns CJ. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg. 2007;392:371–9.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006;312:1171–5.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
   PubMed Web of Science ®Google Scholar
• Webb T. Vascular normalization: study examines how antiangiogenesis therapies work. J Natl Cancer Inst. 2005;97:336–7.
   PubMedGoogle Scholar
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, et al.. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–86.
   PubMed Web of Science ®Google Scholar
• O’Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 1999;5:181–7.
   PubMed Web of Science ®Google Scholar
• Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery. 2004;55:426–32; discussion 432.
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19:7–16.
   PubMedGoogle Scholar
• Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, et al.. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624–8.
   PubMed Web of Science ®Google Scholar
• Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, et al.. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res. 2005;11:4934–40.
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7:1152–60.
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des. 2007;13:3545–58.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, et al.. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2012;107(1):213–21.
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS. 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies. Expert Rev Anticancer Ther. 2011;11(2):161–3.
   PubMedGoogle Scholar
• Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009;6:513–26.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al.. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–24.
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al.. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880–7.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Kalofonos H, Epenetos AA. Monoclonal antibodies. Future potential in cancer chemotherapy. Drugs. 1989;38:645–57.
   PubMed Web of Science ®Google Scholar
• Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther. 2007;6:1909–19.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al.. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.
   PubMed Web of Science ®Google Scholar
• Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, Clynes M, et al.. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. Exp Cell Res. 2012;318(5):641–52.
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, et al.. European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008;26(28):4659–65.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, et al.. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009;101(12):1995–2004.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, et al.. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012; to be published.
   Web of Science ®Google Scholar
• Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, et al.. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009;15(19):6258–66.
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, et al.. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25:1651–7.
   PubMed Web of Science ®Google Scholar
• Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, et al.. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem. 2000;43:3200.
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al.. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178–89.
   PubMed Web of Science ®Google Scholar
• Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al.. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002;16(1):108–10.
   PubMed Web of Science ®Google Scholar
• Brockmann MA, Ulbricht U, Grüner K, Fillbrandt R, Westphal M, Lamszus K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery. 2003;52(6):1391–9
   PubMed Web of Science ®Google Scholar
• Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res. 2003;9(12):4578–85.
   PubMed Web of Science ®Google Scholar
• Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, et al.. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res. 2005;65(20):9355–62.
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al.. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233–42.
   PubMed Web of Science ®Google Scholar
• Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, et al.. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12:985–990.
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G, et al.. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-oncol. 2010;12:466–72.
   PubMed Web of Science ®Google Scholar
• Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13:455–68.
   PubMed Web of Science ®Google Scholar
• Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007;67:2729–35.
   PubMed Web of Science ®Google Scholar
• Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery. 2008;62:31–50; discussion 50–2.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al.. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.
   PubMed Web of Science ®Google Scholar
• Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011;6:2.
   PubMed Web of Science ®Google Scholar
• Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, et al.. Intra-arterial delivery of bevacizumab after blood–brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg. 2012;77(1):130–4.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al.. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817–23.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, et al.. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2009;96:219–230.
   PubMed Web of Science ®Google Scholar
• Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al.. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579–84.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al.. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncol. 2010;12:95–103.
   PubMed Web of Science ®Google Scholar
• Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, et al.. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2009;98:93–99.
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al.. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–42.
   PubMed Web of Science ®Google Scholar
• Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, et al.. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047–51.
   PubMed Web of Science ®Google Scholar
• Lamar RE, Spigel DR, Burris HA, Markus TM, Kuzur M, Ervin T, et al.. Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM). ASCO Meet Abstr. 2009;27;2018.
   Google Scholar
• Wen PY, Alfred Yung WK, Lamborn KR, Dahia PL, Wang YF, Peng B, et al.. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res. 2006;12:4899–907.
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, et al.. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008:26:4659–65.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al.. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359–68.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, et al.. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Clin Neurooncol. 2007;83:53–60.
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, et al.. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). J Clin Neurooncol. 2007;25:2027.
   Google Scholar